{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:21:22Z","timestamp":1791685282025,"version":"4.3.4"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dupilumab demonstrated efficacy in children with asthma in phase 3 VOYAGE (NCT02948959) and open\u2010label extension EXCURSION (NCT03560466) studies. This post hoc analysis assessed dupilumab's long\u2010term efficacy by asthma severity at parent study baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Children (6\u201311\u2009years) with moderate\u2010to\u2010severe type 2 inflammatory asthma (PS baseline blood eosinophils \u2265150 cells\/\u03bcL or fractional exhaled nitric oxide \u226520\u2009ppb) from placebo\u2010controlled VOYAGE who enrolled in EXCURSION received dupilumab every 2\u2009weeks for an additional 52\u2009weeks. We assessed annualized severe exacerbation rates, change in pre\u2010bronchodilator percent predicted forced expiratory volume in 1\u2009second (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) and FEV\n                      <jats:sub>1<\/jats:sub>\n                      <jats:italic>z<\/jats:italic>\n                      \u2010score, and Interviewer\u2010Administered 7\u2010item Asthma Control Questionnaire (ACQ\u20107\u2010IA) score in subgroups with moderate (medium\u2010dose inhaled corticosteroid (ICS), pre\u2010bronchodilator percent predicted FEV\n                      <jats:sub>1<\/jats:sub>\n                      \u2009\u2265\u200980%) and severe (high\u2010dose ICS, pre\u2010bronchodilator percent predicted FEV\n                      <jats:sub>1<\/jats:sub>\n                      \u2009&lt;\u200980%) asthma at parent study baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 179 children (104 with moderate, 75 with severe asthma), dupilumab compared to placebo reduced unadjusted annualized severe exacerbation rates during VOYAGE in children with moderate (0.22 vs. 0.37) and severe (0.41 vs. 1.07) asthma, with sustained reductions in EXCURSION (moderate: 0.07 and 0.07; severe: 0.24 and 0.19). At VOYAGE Week 52, the change from the parent study baseline in pre\u2010bronchodilator percent predicted FEV\n                      <jats:sub>1<\/jats:sub>\n                      was 8.6 versus 2.1 percentage points with dupilumab and placebo in children with moderate asthma, and 16.7 versus 9.8 percentage points in children with severe asthma. Improvements in the change from the parent study baseline in pre\u2010bronchodilator FEV\n                      <jats:sub>1<\/jats:sub>\n                      <jats:italic>z<\/jats:italic>\n                      \u2010scores and ACQ\u20107\u2010IA scores were also observed with dupilumab treatment in both subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long\u2010term dupilumab treatment reduced exacerbation rates and improved lung function and asthma control in children with type 2 asthma irrespective of disease severity, with numerically greater improvements in children with severe asthma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/pai.70196","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:14:19Z","timestamp":1762510459000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab efficacy by disease severity in pediatric type 2 asthma"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-2690","authenticated-orcid":false,"given":"Daniel J.","family":"Jackson","sequence":"first","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Gappa","sequence":"additional","affiliation":[{"name":"Children's Hospital Evangelisches Krankenhaus D\u00fcsseldorf  D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[{"name":"Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2006-7221","authenticated-orcid":false,"given":"Antoine","family":"Deschildre","sequence":"additional","affiliation":[{"name":"Pediatric Pulmonology and Allergy Department, Jeanne de Flandre Hospital CHU Lille, University of Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie","family":"Ross","sequence":"additional","affiliation":[{"name":"UH Rainbow Babies and Children's Hospital  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ledanois","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Miller","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.06.030"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3786"},{"key":"e_1_2_13_4_1","unstructured":"Global Initiative for Asthma.Global strategy for asthma management and prevention 2025. Accessed March 2025.https:\/\/ginasthma.org\/2025\u2010gina\u2010strategy\u2010report\/"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1298443"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323896111"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324022111"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106567"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_13_12_1","unstructured":"European Medicines Agency.Dupixent (dupilumab) European Public Assessment Report.2017. Accessed January 17 2025.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent#overview"},{"key":"e_1_2_13_13_1","unstructured":"US Food and Drug Administration.DUPIXENT\u00ae (dupilumab) US Prescribing Information.2022. Accessed January 17 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s042lbl.pdf"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00303-X"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1178OC"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2962"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.05.034"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8712-1"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851940"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.05.021"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0085-2019"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.0433"}],"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.70196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pai.70196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.70196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:05:57Z","timestamp":1782201957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pai.70196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/pai.70196"],"URL":"https:\/\/doi.org\/10.1111\/pai.70196","archive":["Portico"],"relation":{},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70196"}}